OPRXNasdaqServices-Business Services, NECFiscal year ends December 31
OptimizeRx Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.74+0.24 (+2.82%)
Close on Oct 19, 2026
- Market cap
- $164.19M
- P/E (TTM)
- 36.4
- Dividend yield
- –
OptimizeRx statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Business Services, NEC companies for comparison
Valuation
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Market Cap | $164.63M | $288.87M |
| Enterprise Value | $159.54M | $296.43M |
| PE Ratio | 36.42 | 25.42 |
| PS Ratio | 1.67 | 2.45 |
| PB Ratio | 1.26 | 2.73 |
| P/TBV Ratio | 7.66 | 4.95 |
| P/FCF Ratio | 8.97 | 15.04 |
| P/OCF Ratio | 8.93 | 13.19 |
Enterprise value
| Measure | OptimizeRx | Industry median |
|---|---|---|
| EV / Sales | 1.62 | 2.21 |
| EV / EBITDA | 10.49 | 16.37 |
| EV / EBIT | 14.60 | 21.97 |
| EV / FCF | 8.69 | 15.16 |
Income (trailing twelve months)
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Revenue | $98.65M | $289.17M |
| Gross Profit | $72.24M | $161.98M |
| Operating Income | $10.93M | -$613.24K |
| Pretax Income | $6.78M | -$294.07K |
| Net Income | $4.60M | -$301.07K |
| EBITDA | $15.21M | -$156.35K |
| EPS (Diluted) | $0.24 | $0.00 |
Margins
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Gross Margin | 73.2% | 55.8% |
| Operating Margin | 11.1% | -1.81% |
| Pretax Margin | 6.87% | -0.50% |
| Profit Margin | 4.66% | -1.80% |
| EBITDA Margin | 15.4% | 0.60% |
| FCF Margin | 18.6% | 10.0% |
Returns
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Return on Equity (ROE) | 3.68% | 0.83% |
| Return on Assets (ROA) | 2.76% | -2.82% |
| Return on Invested Capital (ROIC) | 5.77% | -0.05% |
| Return on Capital Employed (ROCE) | 7.07% | -0.44% |
Growth
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -5.82% | 9.72% |
| FCF Growth (YoY) | 77.5% | 17.2% |
| Revenue Growth (3Y CAGR) | 20.6% | 7.66% |
| Revenue Growth (5Y CAGR) | 20.4% | 12.4% |
Balance sheet
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $24.10M | $43.42M |
| Total Debt | $19.01M | $204.00M |
| Net Cash (Debt) | $5.09M | $2.04M |
| Net Cash Per Share | $0.27 | $0.13 |
| Equity (Book Value) | $131.08M | $52.29M |
| Book Value Per Share | $6.96 | $1.90 |
| Tangible Book Value | $21.50M | $3.06M |
| Working Capital | $44.44M | $15.22M |
Financial position
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Current Ratio | 5.58 | 1.40 |
| Quick Ratio | 5.03 | 0.94 |
| Debt / Equity | 0.15 | 0.53 |
| Debt / EBITDA | 1.25 | 2.78 |
| Debt / FCF | 1.04 | 2.83 |
| Net Debt / EBITDA | -0.33 | 1.50 |
| Interest Coverage | 2.34 | -0.66 |
Cash flow (trailing twelve months)
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Operating Cash Flow | $18.43M | $8.52M |
| Capital Expenditures | -$77.00K | -$5.56M |
| Free Cash Flow | $18.36M | $43.71M |
| FCF Per Share | $0.97 | $0.69 |
Efficiency
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Asset Turnover | 0.59 | 0.64 |
| Revenue Per Employee | $948.60K | $392.99K |
| Profits Per Employee | $44.24K | -$4.94K |
| Employee Count | 104 | 544 |
Dividends and yields
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Earnings Yield | 2.79% | -0.85% |
| FCF Yield | 11.2% | 3.98% |
Shares
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Shares Outstanding | 18,836,000 | 60,427,600 |
| Shares Change (YoY) | 2.30% | 2.21% |
| Shares Change (QoQ) | 0.36% | 0.06% |
| Float | 15,179,500 | 53,528,000 |
| Shares Held by Insiders | 19.4% | 13.1% |
| Shares Held by Institutions | 59.6% | 66.9% |
Taxes
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Income Tax | $2.18M | $1.69M |
| Effective Tax Rate | 32.1% | 22.0% |
Scores
| Measure | OptimizeRx | Industry median |
|---|---|---|
| Graham Number | $6.13 | $15.96 |
| Graham Upside | -29.9% | -56.1% |
| Altman Z-Score | 3.43 | 1.51 |
| Piotroski F-Score | 8 | 5 |
Calculated by StockData from OptimizeRx's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.